Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -11.55% is 68% above its 5-year average of -36.34%, near the high end of its 5-year range (-91.36%–-1.31%).
10.46% below its 12-month average of -10.46%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -7.25%.
EBITDA MARGIN
-11.55%
EBITDA MARGIN AVG TTM
-10.46%
EBITDA MARGIN AVG 3Y
-12.28%
EBITDA MARGIN AVG 5Y
-36.34%
EBITDA MARGIN AVG 10Y
-42.10%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-10.46%
CURRENT VS 3Y AVG
+5.96%
CURRENT VS 5Y AVG
+68.22%
CURRENT VS 10Y AVG
+72.56%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Natera, Inc.
Market Cap
$58.77B
EBITDA Margin
-11.55%
TTM Avg
-10.46%
3Y Avg
-12.28%
5Y Avg
-36.34%
Market Cap
$63.32B
EBITDA Margin
26.60%
TTM Avg
24.95%
3Y Avg
24.24%
5Y Avg
23.28%
Market Cap
$53.47B
EBITDA Margin
1.40%
TTM Avg
1.39%
3Y Avg
1.08%
5Y Avg
0.86%
Market Cap
$49.03B
EBITDA Margin
29.55%
TTM Avg
28.88%
3Y Avg
30.96%
5Y Avg
31.73%
Market Cap
$48.72B
EBITDA Margin
23.08%
TTM Avg
23.14%
3Y Avg
23.23%
5Y Avg
22.53%
Market Cap
$47.38B
EBITDA Margin
25.43%
TTM Avg
26.12%
3Y Avg
26.05%
5Y Avg
25.37%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Natera, Inc. (NTRA) | $58.77B | -11.55% | -10.46% | -12.28% | -36.34% |
| Cencora, Inc. (COR)vs › | $60.13B | 1.46% | 1.44% | 1.41% | 1.40% |
| Boston Scientific Corporation (BSX)vs › | $63.32B | 26.60% | 24.95% | 24.24% | 23.28% |
| Cardinal Health, Inc. (CAH)vs › | $53.47B | 1.40% | 1.39% | 1.08% | 0.86% |
| Edwards Lifesciences Corporation (EW)vs › | $49.03B | 29.55% | 28.88% | 30.96% | 31.73% |
| Becton, Dickinson and Company (BDX)vs › | $48.72B | 23.08% | 23.14% | 23.23% | 22.53% |
| Agilent Technologies, Inc. (A)vs › | $47.38B | 25.43% | 26.12% | 26.05% | 25.37% |
| Humana Inc. (HUM)vs › | $46.63B | 1.76% | 1.98% | 3.17% | 4.08% |
| Cigna Corporation (CI)vs › | $71.48B | 4.28% | 4.40% | 4.95% | 5.27% |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $46.04B | 18.31% | 11.44% | 6.73% | 5.67% |
Gross Margin
65.3%
EBITDA Margin
-11.6%
Operating Margin
-10.7%
Net Margin
-7.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -7.25% |
| 2026-03-31 | -10.52% |
| 2025-12-31 | -1.31% |
| 2025-09-30 | -14.81% |
| 2025-06-30 | -18.39% |
| 2025-03-31 | -13.94% |
| 2024-12-31 | -11.96% |
| 2024-09-30 | -7.08% |
| 2024-06-30 | -8.71% |
| 2024-03-31 | -17.31% |
| 2023-12-31 | -23.82% |
| 2023-09-30 | -37.43% |
| 2023-06-30 | -39.65% |
| 2023-03-31 | -53.53% |
| 2022-12-31 | -61.71% |
| 2022-09-30 | -52.50% |
| 2022-06-30 | -68.17% |
| 2022-03-31 | -67.39% |
| 2021-12-31 | -78.99% |
| 2021-09-30 | -91.36% |
| 2021-06-30 | -77.38% |
| 2021-03-31 | -37.95% |
| 2020-12-31 | -63.69% |
| 2020-09-30 | -54.61% |
| 2020-06-30 | -57.19% |
| 2020-03-31 | -35.15% |
| 2019-12-31 | -39.65% |
| 2019-09-30 | -24.55% |
| 2019-06-30 | -35.78% |
| 2019-03-31 | -44.63% |
| 2018-12-31 | -41.51% |
| 2018-09-30 | -38.71% |
| 2018-06-30 | -40.27% |
| 2018-03-31 | -45.97% |
| 2017-12-31 | -80.15% |
| 2017-09-30 | -41.20% |
| 2017-06-30 | -46.95% |
| 2017-03-31 | -75.21% |
| 2016-12-31 | -72.44% |
| 2016-09-30 | -46.22% |
| 2016-06-30 | -40.94% |
| 2016-03-31 | -13.59% |
| 2015-12-31 | -30.57% |
| 2015-09-30 | -43.08% |
| 2015-06-30 | -31.36% |
| 2015-03-31 | -9.77% |
| 2014-12-31 | 11.73% |
| 2014-09-30 | 13.27% |
| 2014-06-30 | 0.09% |
| 2014-03-31 | -22.76% |
| 2013-12-31 | -11.74% |
| 2013-09-30 | -23.76% |
| 2013-03-31 | -203.01% |
